

HIV DART 2010

Frontiers in Drug Development for Antiretroviral Therapies

Scientific Program

Tuesday, December 7, 2010

Abstract **Page**

18:00 Welcome Reception

Wednesday, December 8, 2010

MORNING SESSION

- | | | | | |
|------|---|--|---|---|
| 8:00 | Opening Remarks
Raymond F. Schinazi | <i>Emory University/VA Medical Center, USA</i> | | |
| 8:10 | Presentation of Gertrude Elion Distinguished Lecturer Award
Robert Murphy | <i>Northwestern University, USA</i> | | |
| | Carlos del Rio | <i>Emory University/Grady Memorial Hospital, USA</i> | | |
| 8:20 | Gertrude Elion Distinguished Lecturer Award Lecture
Persistence, Resistance, Diversity: Insights into the HIV-host Interaction
John Coffin | <i>Tufts University, USA</i> | 1 | 3 |

Reservoirs, Persistence and Eradication

- | | | | | |
|---------|---|---|---|---|
| Chairs: | Steven Deeks | <i>University of California, USA</i> | | |
| | Daria Hazuda | <i>Merck & Co., Inc, USA</i> | | |
| 9:05 | State of the Art Lecture: Tackling HIV Latency
Douglas Richman | <i>University of California, San Diego/VA Medical Center, USA</i> | 2 | 3 |
| 9:35 | HIV-1 Utilizes the CXCR4 Chemokine Receptor to Infect Multipotent Hematopoietic Stem and Progenitor Cells
Kathleen Collins | <i>University of Michigan, USA</i> | 3 | 4 |
| 9:55 | Prospects for HIV Eradication
Sharon Lewin | <i>Alfred Hospital, Australia</i> | 4 | 4 |
| 10:15 | Panel Discussion | | | |
| 10:30 | Break | | | |

Immunotherapies

- | | | | | |
|---------|---|---|---|---|
| Chairs: | John Moore | <i>Weill Cornell Medical College, USA</i> | | |
| | Ila Singh | <i>University of Utah, USA</i> | | |
| 10:45 | The PD-1 Inhibitory Co-signaling Pathway in HIV Infection and the Potential for Therapeutic Intervention
Daniel Kaufmann | <i>Harvard University, USA</i> | 5 | 5 |

		Abstract	Page
11:05	Lentiviral Vectors as HIV Vaccine Candidates: A Highly Immunogenic Lentiviral Vaccine Provides Control of Viral Load, Preservation of the CD4 Compartment, and Survival Advantage Post-SIV Challenge Franck Lemiale	6	5
	<i>VIRxSYS Corporation, USA</i>		

11:25 Panel Discussion

Oral Abstract Session I

Chairs: Carlos del Rio *Emory University/Grady Memorial Hospital, USA*
Sharon Lewin *Alfred Hospital, Australia*

11:40	DermaVir Therapeutic HIV Vaccine: Phase I and II Clinical Data in ARV Treated and Naïve HIV ⁺ Subjects Julianna Lisziewicz	48	44
	<i>Genetic Immunity, Hungary</i>		
11:55	The Preclinical and Clinical Chemokine Receptor 2 (CCR2) Activity of TBR 652, a Potent Dual CCR5/CCR2 Antagonist in Phase 2 Development for Treatment of HIV Infection Richard Ogden	53	48
	<i>Tobira Therapeutics, Inc., USA</i>		
12:05	Development of a Cellular Immunotherapy for ART Naïve Patients for the Purpose of Delaying or Preventing Initiation of ART Charles Nicolette	55	50
	<i>Argos Therapeutics, Inc., USA</i>		
12:15	AIC246, a Potent Novel, Well Tolerated Non-Nucleosidic Compound Against Human Cytomegalovirus (HCMV) with Resistance Breaking Potential Helga Rübsamen-Schaeff	54	49
	<i>AiCuris, Germany</i>		

12:30 Lunch

16:00 Poster Session
-18:00

EVENING SESSION

Viral Hepatitis Co-infection and Other HIV Co-morbidities

Chairs: James Rooney *Gilead Sciences, USA*
David Cooper *University of New South Wales National Centre in HIV Epidemiology & Clinical Research, Australia*

18:00	State of the Art Lecture: Liver Disease and Therapy of Hepatitis B Virus Infection in HIV Infected Persons William Mason	7	6
	<i>Fox Chase Cancer Center, USA</i>		
18:30	Co-infection with Hepatitis B Marion Peters	8	7
	<i>University of California, San Francisco, USA</i>		
18:50	Acute Hepatitis C in HIV: Lessons Learned Jürgen Rockstroh	9	8
	<i>University of Bonn, Germany</i>		

	Abstract	Page
19:10 Malignancies in HIV: A Growing Problem Ronald Mitsuyasu <i>University of California, Los Angeles, USA</i>	10	8

19:30 Panel Discussion
-19:45

Thursday, December 9, 2010

MORNING SESSION

Antiretroviral Targets

Chairs: Raymond F. Schinazi *Emory University/VA Medical Center, USA*
Hiroaki Mitsuya *Kumamoto University School of Medicine, Japan and National Cancer Institute, USA*

8:00 Presentation of David Barry DART Achievement Award
Gracia Barry

8:10 David Barry DART Achievement Award Lecture Pharmacokinetic Boosting: A Paradigm Shift in Antiviral Therapy Dale Kempf <i>Abbott Laboratories, USA</i>	11	9
---	----	---

8:55 Discovery of Novel Inhibitors of HIV-1 Reverse Transcriptase by Crystallographic Fragment Screening Eddy Arnold <i>Rutgers University, USA</i>	12	9
--	----	---

9:15 Small Molecule Inhibition of Human Immunodeficiency Virus Type 1 Infection by Virus Capsid Destabilization Christopher Aiken <i>Vanderbilt University, USA</i>	13	10
--	----	----

9:35 HIV Gag and PR: Partners in Resistance to Protease and Maturation Inhibitors Monique Nijhuis <i>University Medical Center Utrecht, the Netherlands</i>	14	10
--	----	----

9:55 Panel Discussion

10:10 Break

Treatment Strategies in Developing Countries

Chairs: Luis Soto-Ramirez *Instituto Nacional de Ciencias Medicas y Nutricion, Mexico*
Dennis Liotta *Emory University, USA*

10:25 Infant HAART in Resource Limited Countries Annelies Van Rie <i>University of North Carolina Chapel Hill, USA</i>	15	11
---	----	----

10:45 Treatment Strategies in Developing Countries Joep Lange <i>University of Amsterdam, the Netherlands</i>	16	12
--	----	----

11:05 Differences between HIV Subtypes in Development of Drug Resistance: The Clustering of Transmitted Resistance Mark Wainberg <i>McGill AIDS Center, Canada</i>	17	12
---	----	----

11:25 Panel Discussion

	Abstract	Page
11:40 Special Lecture: Implications of Lymphatic Tissue Pathology for Early Initiation of ART Ashley Haase <i>University of Minnesota, USA</i>	18	13
Oral Abstract Session II		
Chairs: Leonid Margolis Kathleen Collins <i>National Institutes of Health, USA</i> <i>University of Michigan, USA</i>		
12:10 Complementary Strategies to Block Translocation of HIV-1 Reverse Transcriptase Matthias Götte <i>McGill University, Canada</i>	30	28
12:20 Structure-Guided Development of Antiviral Agents for Treating HIV-1 Infection and AIDS: Non-Peptidyl HIV-1 Protease Dimerization Inhibitors (PDIs) Hiroaki Mitsuya <i>Kumamoto University School of Medicine, Japan</i> <i>and National Cancer Institute, USA</i>	34	31
12:30 Homing Endonucleases for the Targeted Disruption of Integrated HIV Keith Jerome <i>Fred Hutchinson Cancer Research Center, and</i> <i>University of Washington, USA</i>	70	62
12:40 Lunch		
EVENING SESSION		
Poster Discussions		
Chair: Joep Lange <i>University of Amsterdam, the Netherlands</i>		
16:30 Poster Discussion I (Pre-clinical) Brendan Larder <i>RDI, UK</i>		
17:00 Poster Discussion II (Clinical) Richard Pollard <i>University of California, Davis Medical Center, USA</i>		
Inflammation, Pharmacology, Toxicology and Drug Metabolism		
Chairs: Monique Nijhuis William Mason <i>University Medical Center Utrecht, the Netherlands</i> <i>Fox Chase Cancer Center, USA</i>		
17:30 State of the Art Lecture: Lipodystrophy and Metabolic Toxicity of Antiretroviral Therapy David Cooper <i>University of New South Wales National Centre in HIV</i> <i>Epidemiology & Clinical Research, Australia</i>		
18:00 Chronic Inflammation and Medical Complications in HIV David Shepp <i>Hofstra University School of Medicine,</i> <i>North Shore University Hospital, USA</i>	19	14
18:25 HIV, Inflammation, and Cardiovascular Disease Laurence Sperling <i>Emory University School of Medicine, USA</i>	20	14
18:50 Oral Abstract 12 Week Analysis of the SENSE Trial: Etravirine <i>versus</i> Efavirenz in Treatment-naïve Patients Mark Nelson <i>Chelsea and Westminster Hospital, UK</i>	37	35

19:00 Panel Discussion
-19:15

20:00 Gala Party

Friday, December 10, 2010

MORNING SESSION

Preventing Transmission: Microbicides and Other Approaches

Chairs: Douglas Richman *University of California, San Diego/VA Medical Center, USA*
Tom North *Emory University, USA*

8:00 **State of the Art Lecture:** Treatment as Prevention: Five Year Experience 21 15
in British Columbia, Canada
Julio Montaner *BC Centre for Excellence in HIV/AIDS, Canada*

8:30 CCR5 Inhibitors as Vaginal Microbicides 22 15
John Moore *Weill Cornell Medical College, USA*

8:50 Pre-exposure Prophylaxis 23 16
James Rooney *Gilead Sciences, USA*

9:10 Sex is Messy 24 16
Davey Smith *University of California, San Diego, USA*

9:30 Panel Discussion

9:45 **Special Lecture:** Emerging Retroviruses: XMRV: The Link to Prostate Cancer 25 16
and Chronic Fatigue Syndrome
Ila Singh *University of Utah, USA*

10:15 Break

Novel Monitoring and Diagnostic Approaches

Chairs: Marion Peters *University of California, San Francisco, USA*
Robert Murphy *Northwestern University, USA*

10:30 Predicting HIV Response to Antiretroviral Therapy 26 17
Daniel Kuritzkes *Brigham and Women's Hospital, USA*

10:55 Novel Biomarkers of Disease Outcome in Antiretroviral-treated Patients 27 18
Steven Deeks *University of California, San Francisco, USA*

Oral Abstract Session III

Chairs: Robert Murphy *Northwestern University, USA*
David Shepp *Hofstra University School of Medicine,
North Shore University Hospital, USA*

11:20 CMX157 (Hexadecyloxypropyl Tenofovir), a Clinical Stage Antiretroviral with 47 43
Activity against HIV and XMRV
Randall Lanier *Chimerix Inc., USA*

		<u>Abstract</u>	<u>Page</u>
11:30	Anti-HIV Effect <i>In Vitro</i> of Human Milk Glycosaminoglycans Monica Viveros-Rogel	63	56
	<i>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico</i>		
11:40	What Should be the Primary Virological Endpoint in Clinical Trials of Antiretroviral Efficacy?	43	39
	<i>Richard Harrigan</i>		
	<i>BC Centre for Excellence in HIV/AIDS, Canada</i>		
11:50	Pooled Week 48 Efficacy and Safety Results from ECHO and THRIVE, Two Double-blind, Randomized, Phase III Trials Comparing TMC278 <i>versus</i> Efavirenz in Treatment-naïve, HIV-1-infected Patients	45	41
	<i>Katia Boven</i>		
	<i>Tibotec Inc., USA</i>		
12:00	Late Breaker		
12:10	Late Breaker		
12:20	Closing Remarks		
	<i>Raymond F. Schinazi</i>		
	<i>Emory University/VA Medical Center, USA</i>		
12:30	Lunch on your own		